Journal Article

DKFZ-2022-02873

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.

Darawshi, O. ; Muz, B. ; Naamat, S. G. ; Praveen, B. ; Mahameed, M. ; Goldberg, K. ; Dipta, P. ; Shmuel, M. ; Forno, F. ; Boukeileh, S. ; Pahima, H. ; Hermann, J.DKFZ* ; Raab, M. S. ; Poos, A. M. ; Weinhold, N. ; Rosenbluh, C. ; Gatt, M. E. ; Palm, W.DKFZ* ; Azab, A. K. ; Tirosh, B.

2022
Nature Publishing Group London [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41419-022-05421-4

Abstract: Multiple myeloma (MM) causes approximately 20% of deaths from blood cancers. Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs), MM remains incurable due to the development of resistance. mTORC1 is a key metabolic regulator, which frequently becomes dysregulated in cancer. While mTORC1 inhibitors reduce MM viability and synergize with other therapies in vitro, clinically, mTORC1 inhibitors are not effective for MM. Here we show that the inactivation of mTORC1 is an intrinsic response of MM to PI treatment. Genetically enforced hyperactivation of mTORC1 in MM was sufficient to compromise tumorigenicity in mice. In vitro, mTORC1-hyperactivated MM cells gained sensitivity to PIs and hypoxia. This was accompanied by increased mitochondrial stress and activation of the eIF2α kinase HRI, which initiates the integrated stress response. Deletion of HRI elevated the toxicity of PIs in wt and mTORC1-activated MM. Finally, we identified the drug PMA as a robust inducer of mTORC1 activity, which synergized with PIs in inducing MM cell death. These results help explain the clinical inefficacy of mTORC1 inhibitors in MM. Our data implicate mTORC1 induction and/or HRI inhibition as pharmacological strategies to enhance MM therapy by PIs.

---

Contributing Institute(s):

1. A330 NWG Signaltransduktion und Stoffwechsel der Zelle (A330)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---